Immunotherapy drug approved by U.S. FDA
By ELIZABETH LIU | October 27, 2016The U.S. Food and Drug Administration (FDA) expanded approval on Oct. 24 for breakthrough drug pembrolizumab, a first-line treatment for certain patients with metastatic non-small cell lung cancer (NSCLC).

















